Clinical trials: Recurrent Classic Hodgkin Lymphoma, open to volunteers
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory) that have been previously…
- Trial name
- NCT05039073
- Testing
- Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University
Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma
Immunotherapy in Lymphoma
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients.
- Conditions
- Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT06796517
- Testing
- CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate
- Where
- 2 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Sung-Soo Park
Classical Hodgkin Lymphoma, Relapsed Cancer
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not…
- Conditions
- Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT04510636
- Testing
- Pembrolizumab, Bendamustine Hydrochloride
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Hodgkin Lymphoma
PD-1 Inhibitors Maintenance for cHL Post-autoHCT
This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical…
- Trial name
- NCT06812858
- Testing
- Nivolumab, Pembrolizumab
- Where
- 4 sites in Kazakhstan, Russia
- Volunteers
- 83 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase II trial compares the impact of brentuximab vedotin and nivolumab after radiation to standard of care high dose chemotherapy (HDT)-autologous stem cell transplant (ASCT) in standard-risk patients with classic Hodgkin…
- Trial name
- NCT07572123
- Testing
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection
- Volunteers
- 374 people
- Sponsor
- National Cancer Institute (NCI)
Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent
Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
Classical Hodgkin's Lymphoma (cHL) is a rare but highly treatable malignancy of the immune system, primarily affecting young adults.
- Conditions
- Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
- Trial name
- LH_BIO (NCT06822855)
- Where
- 12 sites in Italy
- Volunteers
- 755 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Classical Hodgkin Lymphoma
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.
- Trial name
- REACH-CD30 (NCT07575893)
- Testing
- CD30+ CAR T-cells, Bendamustin, Fludarabine
- Volunteers
- 12 people
- Sponsor
- New York Medical College
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC